CY1105237T1 - Βελτιωμεναι φαρμακευτικαι διαμορφωσεις πepιλαμβανουσαι ritonavir - Google Patents

Βελτιωμεναι φαρμακευτικαι διαμορφωσεις πepιλαμβανουσαι ritonavir

Info

Publication number
CY1105237T1
CY1105237T1 CY20061101354T CY061101354T CY1105237T1 CY 1105237 T1 CY1105237 T1 CY 1105237T1 CY 20061101354 T CY20061101354 T CY 20061101354T CY 061101354 T CY061101354 T CY 061101354T CY 1105237 T1 CY1105237 T1 CY 1105237T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical formulations
improved pharmaceutical
formulations including
including ritonavir
ritonavir
Prior art date
Application number
CY20061101354T
Other languages
English (en)
Inventor
Laman A. Alani
Soumojeet Ghosh
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23269615&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1105237(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of CY1105237T1 publication Critical patent/CY1105237T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Προσφέρονται (προμηθεύονται) βελτιωμέναι φαρμακευτικαί συνθέσεις αι οποίαι περιλαμβάνουν μίαν ή περισσοτέρας ανασταλτικάς ενώσεις πρωτεάσης HIV, έχουσαι βελτιωμένας ιδιότητας διαλύσεως εις μίγμα λιπαρού οξέος, αιθανόλης και ύδατος.
CY20061101354T 1999-06-04 2006-09-21 Βελτιωμεναι φαρμακευτικαι διαμορφωσεις πepιλαμβανουσαι ritonavir CY1105237T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32582699A 1999-06-04 1999-06-04
PCT/US2000/014342 WO2000074677A2 (en) 1999-06-04 2000-05-25 Improved pharmaceutical formulations

Publications (1)

Publication Number Publication Date
CY1105237T1 true CY1105237T1 (el) 2010-03-03

Family

ID=23269615

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20061101354T CY1105237T1 (el) 1999-06-04 2006-09-21 Βελτιωμεναι φαρμακευτικαι διαμορφωσεις πepιλαμβανουσαι ritonavir
CY20091100675T CY1109135T1 (el) 1999-06-04 2009-06-29 Φαρμακευτικο διαλυμα το οποιο περιλαμβανει ριτοναβιρη, εναν διαλυτη (μακριας αλυσιδας λιπαρο οξυ) και νερο

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20091100675T CY1109135T1 (el) 1999-06-04 2009-06-29 Φαρμακευτικο διαλυμα το οποιο περιλαμβανει ριτοναβιρη, εναν διαλυτη (μακριας αλυσιδας λιπαρο οξυ) και νερο

Country Status (33)

Country Link
EP (2) EP1733725B2 (el)
JP (1) JP4753511B2 (el)
KR (1) KR100815412B1 (el)
CN (2) CN100418527C (el)
AR (2) AR032586A1 (el)
AT (2) ATE332132T1 (el)
AU (1) AU778198B2 (el)
BG (1) BG65445B1 (el)
BR (1) BR0007294A (el)
CA (1) CA2371109C (el)
CL (1) CL2008003491A1 (el)
CO (1) CO5160323A1 (el)
CY (2) CY1105237T1 (el)
CZ (1) CZ301308B6 (el)
DE (2) DE60042092D1 (el)
DK (2) DK1183026T3 (el)
ES (2) ES2324549T5 (el)
HK (1) HK1045804A1 (el)
HU (1) HU229501B1 (el)
IL (3) IL146025A0 (el)
MX (1) MXPA01012478A (el)
MY (1) MY127908A (el)
NO (1) NO328968B1 (el)
NZ (1) NZ515016A (el)
PL (1) PL197671B1 (el)
PT (2) PT1183026E (el)
SA (1) SA00210237B1 (el)
SI (2) SI1183026T1 (el)
SK (2) SK287185B6 (el)
TR (1) TR200103488T2 (el)
TW (1) TWI244390B (el)
WO (1) WO2000074677A2 (el)
ZA (1) ZA200108641B (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5090830A1 (es) * 1998-07-20 2001-10-30 Abbott Lab Poliformo de un agente farmaceutico
US7141593B1 (en) 1999-06-04 2006-11-28 Abbott Laboratories Pharmaceutical formulations
MXPA01012478A (es) * 1999-06-04 2003-10-14 Abbott Lab Formulaciones farmaceuticas mejoradas.
WO2001034119A2 (en) 1999-11-12 2001-05-17 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
SI2269591T1 (en) * 2000-01-19 2018-08-31 Abbvie Inc. Improved pharmaceutical formulations
JP2005508294A (ja) * 2001-05-25 2005-03-31 アボット・ラボラトリーズ リトナビルおよび／またはロピナビルを含む軟弾性カプセル
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
EP1976517A1 (en) * 2005-12-30 2008-10-08 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
NO347119B1 (no) * 2006-07-07 2023-05-15 Gilead Sciences Inc Modulatorer av farmakokinetikkegenskaper til terapeutika
AU2013204805C1 (en) * 2006-07-07 2017-03-09 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
AU2015258296B2 (en) * 2006-07-07 2017-08-17 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
PT2487165T (pt) 2006-07-07 2016-11-18 Gilead Sciences Inc Moduladores de propriedades farmacocinéticas de agentes terapêuticos
AU2015234299B2 (en) * 2006-07-07 2017-03-09 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
CA2669938C (en) 2006-11-15 2016-01-05 Abbott Laboratories Solid pharmaceutical dosage formulations
AU2013204815B2 (en) * 2007-02-23 2015-05-07 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
DK2487162T3 (en) 2007-02-23 2016-10-24 Gilead Sciences Inc Modulators of Pharmacokinetic properties terapeutikas
ES2601820T3 (es) * 2007-02-23 2017-02-16 Gilead Sciences, Inc. Moduladores de propiedades terapéutica de las farmacocinéticas
AU2015204378B2 (en) * 2007-02-23 2017-03-09 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
CN101796040A (zh) * 2007-07-06 2010-08-04 吉里德科学公司 治疗剂的药代动力学特性调节剂
EP2231628B1 (en) 2008-01-04 2015-10-28 Gilead Sciences, Inc. Inhibitors of cytochrome p450
UA108738C2 (uk) * 2009-04-03 2015-06-10 Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5539122A (en) * 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
IL110752A (en) † 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) † 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US5952004A (en) * 1994-03-18 1999-09-14 Shire Laboratories Inc. Emulsified drug delivery systems
DE4431489A1 (de) * 1994-09-03 1996-03-07 Heidelberger Baustofftech Gmbh Schnellhärtende aminosilanvernetzende Silikonmassen
US5567823A (en) * 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
EP1295874A3 (en) * 1995-12-13 2003-04-02 Abbott Laboratories Retroviral protease inhibiting compounds
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
CO5090830A1 (es) * 1998-07-20 2001-10-30 Abbott Lab Poliformo de un agente farmaceutico
MXPA01012478A (es) * 1999-06-04 2003-10-14 Abbott Lab Formulaciones farmaceuticas mejoradas.

Also Published As

Publication number Publication date
ATE429224T1 (de) 2009-05-15
ES2324549T5 (es) 2012-10-31
BG106239A (en) 2002-08-30
SK17202001A3 (sk) 2002-03-05
PL197671B1 (pl) 2008-04-30
DE60042092D1 (de) 2009-06-04
NO20015670D0 (no) 2001-11-20
PT1183026E (pt) 2006-11-30
MY127908A (en) 2006-12-29
ZA200108641B (en) 2003-01-20
ATE332132T1 (de) 2006-07-15
NO328968B1 (no) 2010-06-28
ES2265946T3 (es) 2007-03-01
ES2324549T3 (es) 2009-08-10
SK286305B6 (en) 2008-07-07
CO5160323A1 (es) 2002-05-30
AR032586A1 (es) 2003-11-19
CY1109135T1 (el) 2014-07-02
CN100418527C (zh) 2008-09-17
JP2003501386A (ja) 2003-01-14
CL2008003491A1 (es) 2009-03-06
AU778198B2 (en) 2004-11-25
BR0007294A (pt) 2002-08-27
NZ515016A (en) 2004-02-27
CN1353607A (zh) 2002-06-12
KR20020011994A (ko) 2002-02-09
CA2371109C (en) 2011-04-26
PL351943A1 (en) 2003-07-14
CA2371109A1 (en) 2000-12-14
TWI244390B (en) 2005-12-01
WO2000074677A2 (en) 2000-12-14
EP1733725A1 (en) 2006-12-20
SI1733725T2 (sl) 2012-10-30
HUP0201591A2 (en) 2002-09-28
KR100815412B1 (ko) 2008-03-20
DE60029219T2 (de) 2007-06-28
IL146025A0 (en) 2002-07-25
HU229501B1 (hu) 2014-01-28
NO20015670L (no) 2001-11-20
IL216686A (en) 2014-01-30
MXPA01012478A (es) 2003-10-14
DK1733725T4 (da) 2012-09-17
EP1733725B2 (en) 2012-08-08
CZ301308B6 (cs) 2010-01-06
SI1733725T1 (sl) 2009-08-31
SA00210237B1 (ar) 2006-11-07
HUP0201591A3 (en) 2002-10-28
HK1045804A1 (en) 2002-12-13
IL146025A (en) 2012-04-30
CZ20014293A3 (cs) 2002-03-13
CN101361723B (zh) 2013-11-06
CN101361723A (zh) 2009-02-11
AR064309A2 (es) 2009-03-25
WO2000074677A3 (en) 2001-02-22
EP1183026B1 (en) 2006-07-05
DE60029219D1 (de) 2006-08-17
SK287185B6 (sk) 2010-02-08
JP4753511B2 (ja) 2011-08-24
EP1733725B1 (en) 2009-04-22
PT1733725E (pt) 2009-06-30
TR200103488T2 (tr) 2002-04-22
DK1183026T3 (da) 2006-11-06
AU5287700A (en) 2000-12-28
BG65445B1 (bg) 2008-08-29
EP1183026A2 (en) 2002-03-06
IL216686A0 (en) 2012-01-31
DK1733725T3 (da) 2009-08-03
SI1183026T1 (sl) 2006-10-31

Similar Documents

Publication Publication Date Title
CY1105237T1 (el) Βελτιωμεναι φαρμακευτικαι διαμορφωσεις πepιλαμβανουσαι ritonavir
ATE398997T1 (de) Selbst-nanoemulgierende ölige formulierung zur verabreichung von schwer wasserlöslichen arzneimitteln
CY1120408T1 (el) Βελτιωμενες φαρμακοτεχνικες μορφες
PA8518801A1 (es) Derivados de 2-aminocarbonil-9h-purina
CY1105896T1 (el) Χρησιμοποιηση ιδεβενονης δια την προστασια σκευασματων
DE69910230D1 (de) Paclitaxel enthaltende arzneimittel
AR023423A1 (es) Derivados de adamantano, procedimientos para su preparacion, composicion farmaceutica, procedimiento para la preparacion de la composicion farmaceutica, yuso de dichos derivados para la manufactura de medicamentos
PA8453201A1 (es) Formulaciones farmaceuticas que contienen voriconazol
CY1110906T1 (el) Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης
HUP0401811A2 (hu) Javított vízoldékonyságú gyógyszerkészítmény és eljárás az előállítására
CY1105934T1 (el) Φαρμακευτικη συνθεση που αποτελειται απο αναστολεα πενινης μη πεπτιδιου και επιφανειοδραστικο παραγοντα
SE0003476D0 (sv) Compounds
TR200103151T2 (tr) Karboksipeptidaz U inhibitörü ile trombin inhibitörünü içeren farmasötik bir formülasyon.
IT1318401B1 (it) Derivati di n-desacetiltiocolchicina e composizioni farmaceutiche cheli contengono.
IT1318654B1 (it) Composizioni farmaceutiche comprendenti agenti antiinfiammatori e lorousi.
CR6829A (es) Derivados de 2-aminocarbonil-9h-purina
ECSP982538A (es) Formulaciones farmaceuticas que contienen variconazol
ATE284685T1 (de) Stabile pharmazeutische nimesulidverbindungen